Resistance to targeted therapy in leukaemia.
Griffin
James D
JD
Leukemia Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA. james_griffin@dfci.harvard.edu
D001549:Benzamides; D004351:Drug Resistance / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics; D010879:Piperazines; D017354:Point Mutation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate